Some see indexes' slip as healthy

Investors grabbed financial shares, and stocks spent most of the day on the plus side. Gainers led losers.

March 17, 2009 at 1:39AM

NEW YORK - Wall Street's big rally fizzled -- and maybe that's OK.

Analysts said Monday's pullback after a four-session surge didn't necessarily signal that traders were reconsidering their newfound optimism about financial stocks, a main driver behind last week's advance.

In fact, some viewed the measured easing in stocks as reassuring after a surge of more than 9 percent in major indicators last week, more than the market has moved in some years.

"This is healthy," said Dave Rovelli, managing director of trading at brokerage Canaccord Adams in New York. "The best thing for this market is that we don't go up aggressively. A steady rise of a few up days, then a down day would be a lot better than 1,000 points up."

Stocks rose for much of the session as investors snapped up hard-hit financial shares. Comments from Federal Reserve Chairman Ben Bernanke and reassuring news from a British bank eased some worries about the overall economy and prospects for financial companies struggling with bad debt.

Bernanke said Sunday the recession would probably end this year if the government's efforts to revive the banking industry succeed. In an interview with CBS' "60 Minutes," Bernanke said fixing the economy will require getting banks to lend more freely and financial markets to work more normally again.

On Monday, the Dow slipped 7.01, or 0.1 percent, to 7,216.97. The blue chips rose as much as 169 points during the session.

The Standard & Poor's 500 index fell 2.66, or 0.4 percent, to 753.89, while the tech-heavy Nasdaq composite index fell 27.48, or 1.9 percent, to 1,404.02.

More stocks rose than fell even as the major indicators lost ground. Advancing issues outnumbered decliners by about 3 to 2 on the New York Stock Exchange, where consolidated volume came to 7.6 billion shares compared with 6.7 billion shares traded Friday.

Light, sweet crude rose $1.10 to settle at $47.35 per barrel on the New York Mercantile Exchange.

ASSOCIATED PRESS

about the writer

about the writer

More from Business

See More
card image
Provided by Exact Sciences

The late Dr. David Ahlquist co-invented ColoGuard, which is helping drive Abbott Laboratories’ acquisition of Exact Sciences. After an ALS diagnosis in 2019, Ahlquist wasn’t done inventing.

card image
card image